Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2003
12/18/2003WO2003082192A3 Certain pharmaceutically useful substituted aminoalkyl heterocycles
12/18/2003WO2003074504A3 Process and intermediates for preparing phenylthiomethyl-thiazoles or oxazoles
12/18/2003WO2003074500A3 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
12/18/2003WO2003072537A3 Selective protein tyrosine phosphatatase inhibitors
12/18/2003WO2003066630A3 Quinolinone derivatives for treating cell proliferation related disorders
12/18/2003WO2003057244A3 Use of amylin agonists to modulate triglycerides
12/18/2003WO2003051917A3 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/18/2003WO2003051307A3 Materials and methods for the treatment or prevention of obesity
12/18/2003WO2003045362A3 Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
12/18/2003WO2003044021A3 Substituted indolizine-like compounds and methods of use
12/18/2003WO2003040309A3 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
12/18/2003WO2003029437A3 Secreted proteins
12/18/2003WO2003028712A3 Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
12/18/2003WO2003022804A9 Method for the preparation of crystalline tetrahydrobenzothiepines
12/18/2003WO2003014342A3 Identification of a dna variant associated with adult type hypolactasia
12/18/2003WO2003000864A8 Nucleic acid-associated proteins
12/18/2003WO2002092781A3 Peptide compounds for counteracting reactive oxygen species and free radicals
12/18/2003WO2002090375A3 Liver x receptor agonists
12/18/2003WO2002081668A3 Desaturase genes and uses thereof
12/18/2003WO2002058724A3 Use of lp82 to treat body weight disorders
12/18/2003WO2002047716A3 Chronic treatment regimen using glucagon-like insulinotropic peptides
12/18/2003WO2002038561A8 Indolylmaleimide derivatives as protein kinase c inhibitors
12/18/2003WO2002007678A3 Mu-conopeptides
12/18/2003US20030232990 For therapy of arteriosclerosis and dyslipidaemias
12/18/2003US20030232887 Preparation and use of a stable formulation of allosteric effector compounds
12/18/2003US20030232883 N-acylamino benzyl ether derivatives
12/18/2003US20030232875 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
12/18/2003US20030232869 N3 alkylated benzimidazole derivatives as MEK inhibitors
12/18/2003US20030232868 Cyclic carboxylic acids as integrin antagonists
12/18/2003US20030232865 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases
12/18/2003US20030232864 Novel Compounds and compositions as protease inhibitors
12/18/2003US20030232863 Cathepsin cysteine protease inhibitors
12/18/2003US20030232859 Antiinflammatory agents; for treatment of rheumatoid arthritis and multiple sclerosis
12/18/2003US20030232853 Azabicyclic compounds for the treatment of disease
12/18/2003US20030232849 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/18/2003US20030232846 Caspase inhibitors and uses thereof
12/18/2003US20030232845 Enzyme hydrolase inhibitors such as 1-ethyl-3,7-dihydro-8-((1 R,2R)-(hydroxycyclopentyl)amino)-3-(2-hydroxyethyl)-7-((3-bromo-4 -methoxyphenyl)methyl)-1H-Purine-2,6-dione, used for physiological effects
12/18/2003US20030232841 Amides such as 5-(2-(4-methylpiperazin-1-yl)-phenyl)-furan-2-carboxylic acid 4-chlorobenzylamide, used as antidepressants and for prophylaxis of headaches
12/18/2003US20030232831 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
12/18/2003US20030232823 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
12/18/2003US20030232819 Monoamine transporter inhibitors; used for early diagnosis and treatment of neurological and psychiatric conditions
12/18/2003US20030232815 Non-peptidic cyclophilin binding compounds and their use
12/18/2003US20030232814 Novel compounds and their use
12/18/2003US20030232813 Novel amino substituted pyrimidinone derivatives
12/18/2003US20030232810 Bicyclic cyclohexylamines and their use as nmda receptor antagonists
12/18/2003US20030232797 Useful as immunomodulating and antiinflammatory compounds and in treatment of cardiovascular disease and cancer
12/18/2003US20030232796 Nanoparticulate polycosanol formulations & novel polycosanol combinations
12/18/2003US20030232795 Administering selective estrogen receptor modulators that possesses tissue-specific ER agonist activity
12/18/2003US20030232793 Comprising hyperglycemia, insulin dependent diabetes mellitus, impaired glucose tolerance, hyperinsulinemia, insulin insensitivity, diabetes related diseases
12/18/2003US20030232783 Partial and full agonists of A1 adenosine receptors
12/18/2003US20030232763 Reducing blood glucose concentrations, weight loss, and treating diseases and conditions mediated by the cyclooxygenase-2 and 5-lipoxygenase enzymes; an enzyme inhibitors
12/18/2003US20030232761 Novel analogues of glucose-dependent insulinotropic polypeptide
12/18/2003US20030232754 Use of GLP-1 peptides
12/18/2003US20030232752 Proliferated cell lines and uses thereof
12/18/2003US20030232748 Insulin aspart and insulin detemir in a specific ratio; antidiabetic agent
12/18/2003US20030232741 Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
12/18/2003US20030232349 Nucleic acid and amino acid sequences of proteases and the use of these sequences in the diagnosis and treatment of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, and neurological disorders
12/18/2003US20030232099 Powder and an extract of lotus root joints; improves insulin resistance, for diabetes, obesity, hyperlipidemia, hypertension, thrombosis, Alzheimer's disease and senility
12/18/2003US20030232078 Formulation & dosage form for the controlled delivery of therapeutic agents
12/18/2003US20030232077 Rapidly disintegrating tablet
12/18/2003US20030232067 Producing a blunted glycemic response in a diabetic patient by administering pullulan
12/18/2003CA2497609A1 Non-peptidic brs-3 agonists
12/18/2003CA2490037A1 Galactosyl isomalt, a method for producing it and its use
12/18/2003CA2488798A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488760A1 N-benzoylureidocinnamate derivatives, method for production and use thereof
12/18/2003CA2488618A1 Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders
12/18/2003CA2488617A1 Nanoparticulate sterol formulations and sterol combinations
12/18/2003CA2488613A1 Novel formate salt of o-desmethyl-venlafaxine
12/18/2003CA2488602A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488498A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations
12/18/2003CA2488403A1 Pharmaceutical formulation
12/18/2003CA2488402A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003CA2487924A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003CA2487838A1 Methods and compounds for inhibiting the cytokine or biological activity of mif
12/18/2003CA2487413A1 Methods of treating angiogenesis, tumor growth, and metastasis
12/18/2003CA2486584A1 Compositions and methods for treating diabetes
12/18/2003CA2486581A1 Substituted phenylsulfonamide inhibitors of beta amyloid production
12/18/2003CA2486491A1 4-(aryl or heteroaryl)-2-butylamine derivatives and their use as glucocorticoid ligans
12/18/2003CA2486362A1 Novel recombinant anticoagulant proteins
12/18/2003CA2485874A1 T cell receptor cdr3 sequences and methods for detection
12/17/2003EP1371728A1 Gene encoding adseverin
12/17/2003EP1371650A1 Activator for peroxisome proliferator-activated receptor
12/17/2003EP1371368A1 Salvianolic acid components as lipase inhibitors
12/17/2003EP1371367A1 Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases
12/17/2003EP1371289A1 Choline-silicic acid complex
12/17/2003EP1370662A2 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
12/17/2003EP1370659A2 Proteins, polynucleotides encoding them and methods of using the same
12/17/2003EP1370588A2 Human monoclonal antibodies to fc alpha receptor (cd89)
12/17/2003EP1370586A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370584A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370583A1 Polypeptides and nucleic acids for bolekine
12/17/2003EP1370568A1 Chemical compounds
12/17/2003EP1370564A2 Resveratrol-phospholipids complexes
12/17/2003EP1370561A2 Tetrahydro-pyrazino[1,2-a]indoles for the treatment of central nervous disorders
12/17/2003EP1370559A1 Triazolopyridines as anti-inflammatory agents
12/17/2003EP1370558A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists
12/17/2003EP1370554A1 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
12/17/2003EP1370548A1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same
12/17/2003EP1370546A2 Novel amines as histamine-3 receptor ligands and their therapeutic applications
12/17/2003EP1370542A1 Bicyclic guanidine derivatives and therapeutic uses thereof
1 ... 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 ... 1298